Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets ...
From static to adaptive: Networks are replacing periodic baseline updates with continuous calibration that evolves alongside real-world conditions. Reducing false alarms: Recursive learning helps AI ...
Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
Recursion, a company that uses machine learning for drug discovery, is partnering with Roche and its subsidiary Genentech to identify novel drug targets and develop drugs against them. The firms will ...
SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automated, experimental biology with artificial intelligence to discover novel treatments that extend beyond our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results